CASTLEFORD, England, August 30, 2012 /PRNewswire/ --
We are pleased to announce the launch of generic Irbesartan tablets.
(Photo: http://photos.prnewswire.com/prnh/20120830/559013 )
Irbesartan is a generic version of Aprovel® (Irbesartan) by Sanofi Pharma Bristol-Myers Squibb SNC. It is indicated in the treatments of essential hypertension and renal disease in patients with hypertension and type 2 diabetes mellitus as part of an antihypertensive medicinal product regimen (please see section 5.1 of the SPC for further details).
Irbesartan tablets are available immediately in the award-winning Teva 360 livery as follows:
Strength 75mg 150mg 300mg
Pack size 28 28 28
Brand Price GBP9.69 GBP11.84 GBP15.93
Initial Teva Retail
Price GBP2.42 GBP2.96 GBP3.98
Kim Innes, Commercial Director at Teva said: "We've launched 22 products this year including now eleven day-one patent expiries in a variety of strengths and pack sizes.
"It's good for Pharmacy because patent expiries provide them with the opportunities for increasing margins and keeping costs down. But, importantly, it also means that we continue to help save the NHS over £9bn a year."
New or existing customers can order through their local Teva Territory Sales Manager, through major wholesalers, or call 0800-085-8621.
To find out more about Teva UK Limited, visit http://www.tevauk.com.
Notes to Editors:
About Teva UK Limited
Teva UK Limited is one of the UK's top ten pharmaceutical manufacturers, with a presence in the generics, branded respiratory and hospitals markets. It has the widest range of any UK generic pharmaceutical company and markets solid and liquid dose, injectable and respiratory medicines to healthcare professionals. The company is part of Teva Pharmaceutical Industries Ltd.
About Teva Pharmaceutical Industries Ltd
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) is a leading global pharmaceutical company, committed to increasing access to high-quality healthcare by developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients. Headquartered in Israel, Teva is the world's leading generic drug maker, with a global product portfolio of more than 1,300 molecules and a direct presence in about 60 countries. Teva's branded businesses focus on CNS, oncology, pain, respiratory and women's health therapeutic areas as well as biologics. Teva currently employs approximately 46,000 people around the world and reached $18.3 billion in net revenues in 2011.
For media enquiries, contact the Teva UK Limited Media team on +44(0)1977-628500, or email media.enquiries@tevauk.com.
Share this article